4-EA-NBOMe is asubstituted amphetamine and25-NB derivative which has been sold as adesigner drug. It was first identified by a forensic laboratory in Germany in 2014,[1] but while its analytical properties and metabolism have been studied,[2][3][4] its pharmacology remains unknown.
^Westphal F, Girreser U, Waldmüller D (September 2016). "Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs".Drug Testing and Analysis.8 (9):910–9.doi:10.1002/dta.1889.PMID26606897.
^Caspar AT, Westphal F, Meyer MR, Maurer HH (January 2018). "LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques".Analytical and Bioanalytical Chemistry.410 (3):897–912.doi:10.1007/s00216-017-0526-0.PMID28762065.S2CID206923339.
^Caspar AT, Meyer MR, Maurer HH (March 2018). "Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach".Toxicology Letters.285:1–8.doi:10.1016/j.toxlet.2017.12.017.PMID29277574.
